

C L A I M S

1. Use of the Anapsos, a natural extract isolated from the rhizomes of *Polypodium*, comprising a water-soluble fraction, a lipid soluble fraction and a pharmaceuti-
5 cally acceptable carrier for the manufacture of a pharmaceutical medicament for regulation of the expression of adhesion molecules.
- 10 2. The use of claim 1, wherein the regulation of the expression of adhesion molecules is characterized by a reduction of the expression of the alpha chains of the integrin β -2 and/or the beta chain of the integrin β -2.
- 15 3. The use of claim 1, wherein the regulation of the expression of adhesion molecules is characterized by a reduction of the expression of the CD54.
4. The use of claim 1, wherein the regulation of the ex-
20 pression of adhesion molecules is characterized by a decrease in the amount of the differentiation antigens CD11b and/or CD6L.
5. The use of claim 1, wherein the medicament is used as
25 an anti-inflammatory and/or immuno-modulatory agent and the medicament is characterized by its capacity for regulation of the expression of adhesion molecules.
6. Use of the Anapsos, a natural extract isolated from
30 the rhizomes of *Polypodium*, comprising a water-soluble fraction, a lipid soluble fraction and a pharmaceuti- cally acceptable carrier for the manufacture of a pharmaceutical medicament for normalizing the lymphocyte

CD4+CD29+CD45RA+ populations in pathologies where said populations are increased.

- 5 7. The use of claim 6, for the treatment of multiple sclerosis.